2012
DOI: 10.1186/1471-2490-12-19
|View full text |Cite
|
Sign up to set email alerts
|

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0
1

Year Published

2013
2013
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 41 publications
0
6
0
1
Order By: Relevance
“…[21][22][23] For example, patients dissatisfied with previous extended release antimuscarinic therapy experienced efficacy and a worthwhile increase in total treatment duration by switching to darifenacin 21 and fesoterodine. 22 Similarly, an open-label study found that patients with insufficient subjective improvement in urgency with tolterodine ER 4 mg had significantly reduced OAB symptoms and improvements in HRQL and social interaction when switched to solifenacin 5/10 mg. 23 However, in a Norwegian study of prescription data, overall 1-year persistence for new users was 38.0%, but only 10.3% switched from their initial antimuscarinic, and 51.7% discontinued without switching. 24 The majority of patients in our study also received just one line of treatment, with only 12.5% switching therapies, and only 1.5% receiving three lines of medication.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…[21][22][23] For example, patients dissatisfied with previous extended release antimuscarinic therapy experienced efficacy and a worthwhile increase in total treatment duration by switching to darifenacin 21 and fesoterodine. 22 Similarly, an open-label study found that patients with insufficient subjective improvement in urgency with tolterodine ER 4 mg had significantly reduced OAB symptoms and improvements in HRQL and social interaction when switched to solifenacin 5/10 mg. 23 However, in a Norwegian study of prescription data, overall 1-year persistence for new users was 38.0%, but only 10.3% switched from their initial antimuscarinic, and 51.7% discontinued without switching. 24 The majority of patients in our study also received just one line of treatment, with only 12.5% switching therapies, and only 1.5% receiving three lines of medication.…”
Section: Discussionmentioning
confidence: 99%
“…There were 47 patients with missing data on age or gender who were excluded from further analysis. There were 70% women (22,312) and 30% men (9,395); most were ≥65 years old ( Figure 1). The majority started OAB therapy on oxybutynin (Table 1).…”
Section: Patient Distributionmentioning
confidence: 99%
“…Fesoterodine has greater bioavailability and therefore a greater possibility of exerting therapeutic effects. The improved efficacy of the higher fesoterodine dose (8 mg) has been established in clinical trials [ 22 , 25 , 39 ] and primary medical practice [ 40 ]; this dose was used by 57% of patients taking fesoterodine in our study.…”
Section: Discussionmentioning
confidence: 99%
“…The utility of multiple doses is based on the assumption of a dose-response effect. The clearly dose-response provided by fesoterodine has been shown in several clinical trials and in routine medical practice [6] [11] [25] [36]. Several studies of solifenacin flexible-dose have been carried out, but direct comparison data between non-escalator and escalator patients have not been finally published [29] [37].…”
Section: Discussionmentioning
confidence: 99%